Novel antifungal drugs

被引:64
作者
DiDomenico, B [1 ]
机构
[1] Schering Plough Res Inst, Kenilworth, NJ 07033 USA
关键词
D O I
10.1016/S1369-5274(99)00009-0
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
There have been many new developments in antifungal therapy in the past few years. Some antifungal drugs have been reformulated to reduce toxicity (e.g, new lipid formulations of polyenes), and new derivatives of drugs have been developed to enhance potencies. The search for unique drug targets will be enhanced by the availability of sequencing data from whole genome sequencing projects.
引用
收藏
页码:509 / 515
页数:7
相关论文
共 85 条
[71]  
SOBEL JD, 1998, 38 ANN INT C ANT AG, P478
[72]  
SORENSEN KN, 1998, 38 ANN INT C ANT AG, P469
[73]   In vitro and in vivo antifungal activity of amphotericin B lipid complex: Are phospholipases important? [J].
Swenson, CE ;
Perkins, WR ;
Roberts, P ;
Ahmad, I ;
Stevens, R ;
Stevens, DA ;
Janoff, AS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (04) :767-771
[74]   BIOLOGICAL PROPERTIES OF AUREOBASIDIN-A, A CYCLIC DEPSIPEPTIDE ANTIFUNGAL ANTIBIOTIC [J].
TAKESAKO, K ;
KURODA, H ;
INOUE, T ;
HARUNA, F ;
YOSHIKAWA, Y ;
KATO, I ;
UCHIDA, K ;
HIRATANI, T ;
YAMAGUCHI, H .
JOURNAL OF ANTIBIOTICS, 1993, 46 (09) :1414-1420
[75]   Roaming through astrophysics [J].
van de Hulst, HC .
ANNUAL REVIEW OF ASTRONOMY AND ASTROPHYSICS, 1998, 36 :1-16
[76]   Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis [J].
Verweij, PE ;
Oakley, KL ;
Morrissey, J ;
Morrissey, G ;
Denning, DW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (04) :873-878
[77]   In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates [J].
Verweij, PE ;
Mensink, M ;
Rijs, AJMM ;
Donnelly, JP ;
Meis, JFGM ;
Denning, DW .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (03) :389-392
[78]  
Viviani MA, 1998, MED MYCOL, V36, P194
[79]  
WAKAI Y, 1998, 38 INT C ANT AG CHEM, pF143
[80]   Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients [J].
Walsh, TJ ;
Yeldandi, V ;
McEvoy, M ;
Gonzalez, C ;
Chanock, S ;
Freifeld, A ;
Seibel, NI ;
Whitcomb, PO ;
Jarosinski, P ;
Boswell, G ;
Bekersky, I ;
Alak, A ;
Buell, D ;
Barret, J ;
Wilson, W .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2391-2398